Tolmar is committed to protecting your personal privacy. We handle personal information with the utmost respect and assure that all information submitted on the Tolmar site will remain strictly confidential. Tolmar requires that any person or organization providing products and/or services to our clients on our behalf protect the confidentiality of Tolmar’s customer information.
Unless Tolmar receives written permission from an individual, we will not:
The Tolmar site collects only information provided “voluntarily” when using or registering with us on this site. Such information may include:
The information gathered from each client is used internally to process proposals, ensure proper billing, service an account and offer other employment related products that may better serve your needs.
This privacy policy applies only to the information that is collected on Tolmar’s website. It does not apply to any information collected through other methods or sources, including sites owned or operated by our affiliate business partners.
Tolmar works closely with affiliated businesses partners that may have links on our website. Please remember that when you use a link to go from Tolmar’s website to another website, our Privacy Policy no longer applies.
Any browsing and interaction on any third party’s website, including any site that has a link on Tolmar’s website, is subject to the policies and rules of that website.
Tolmar reserves the right to change, modify, or amend our privacy policy as needed; we intend to maintain a policy that is at the forefront of privacy and security principles. Tolmar takes privacy matters seriously; if there are any changes to our privacy policy statement, we will place an updated version on this page. Tolmar encourages site users and visitors to check our privacy policy regularly to stay informed of any policy updates or changes.
Thank you for choosing Tolmar. We appreciate your business and the opportunity to serve you.
If you have any questions, concerns or comments regarding this privacy policy, please feel free to contact Tolmar at:
Tolmar, Inc
701 Centre Ave
Fort Collins, CO 80526
970-212-4500
1-877-4Tolmar (1-877-486-5627)
If you are a California resident, the information below may apply to you in addition to our Privacy Policy. This below information uses certain terms that have the meanings given to them by the California Consumer Privacy Act.
We only share your personal information with the categories of third parties for the business and commercial purposes described below. We do not sell or rent personal information to third parties, including for their own marketing purposes.
During the past 12 months, we may have:
a. Collected the following categories of personal information about you:
b. Collected personal information about you for the following business or commercial purposes:
c. Shared your personal information with the following categories of third parties:
d. Disclosed for a business purpose the following categories of personal information about you:
Subject to certain exceptions, California residents have the right to make the following requests, at no charge, up to twice every 12 months:
We will not discriminate against you for exercising these rights.
Submitting Requests. To exercise your rights please submit a request, or have an authorized agent submit a request on your behalf, to info@tolmar.com or call the following toll-free telephone number 1-844-4TOLMAR. We will respond to your request consistent with applicable law.
RUBRACA® (rucaparib) is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.
In ARIEL3, of patients with a germline and/or somatic BRCA mutation treated with RUBRACA, MDS/AML occurred in 9 out of 129 (7%) patients treated with RUBRACA and 4 out of 66 (6%) patients treated with placebo. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.2 to 4.7 years.
Most common adverse reactions of patients with BRCA-mutated mCRPC in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia (62%), nausea (52%), anemia (43%), AST/ALT elevation (33%), decreased appetite (28%), rash (27%), constipation (27%), thrombocytopenia (25%), vomiting (22%), and diarrhea (20%).
